The Journey of Rosuvastatin
The Hydrophilic Statin Advantage
Rosuvastatin, the most hydrophilic statin, relies on active organic anion transporters for hepatic uptake rather than passive diffusion, achieving high liver-to-plasma concentration ratios, potently inhibiting HMG-CoA reductase to reduce cholesterol synthesis, and undergoing minimal CYP metabolism — giving it fewer drug interactions than lipophilic statins.
Absorption
Rosuvastatin is absorbed from the small intestine with oral
bioavailability of approximately 20% — low compared to lipophilic statins, reflecting incomplete
absorption and significant first-pass hepatic extraction rather than presystemic degradation.
Peak plasma concentrations occur within 3-5 hours. Food reduces peak concentration but not
overall AUC. The drug is not significantly metabolized in the gut wall. As with all statins,
the low systemic bioavailability is a pharmacological feature rather than a limitation, because
the liver is the primary target organ for cholesterol lowering. Rosuvastatin's hydrophilicity
(logP ≈ -0.33) means that passive intestinal absorption is limited; uptake through OATP2B1
transporters in the intestinal epithelium facilitates some absorption. Antacids containing
magnesium/aluminum hydroxide reduce rosuvastatin absorption by approximately 50% when taken
simultaneously, likely through chelation.
Distribution
Following absorption, rosuvastatin is selectively transported
into hepatocytes by OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3), organic anion transporting
polypeptides expressed on the hepatocyte sinusoidal membrane. This active uptake creates
hepatic concentrations far exceeding plasma levels — the basis for hepatic selectivity and the
primary determinant of pharmacological effect. Plasma protein binding is 88%, primarily to
albumin. Volume of distribution is approximately 134 L. Tissue distribution beyond the liver
is limited by rosuvastatin's hydrophilicity — it does not readily penetrate CNS, skeletal muscle,
or adipose tissue, compared to lipophilic statins like simvastatin and lovastatin. This reduced
peripheral tissue penetration is proposed to underlie its lower incidence of statin-associated
myopathy, though the clinical evidence is not definitive.
Wirkmechanismus
Rosuvastatin competitively inhibits 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis.
The enzyme catalyzes the conversion of HMG-CoA to mevalonate (an early precursor of cholesterol).
Rosuvastatin's open hydroxy acid form (the active form) binds the active site with a Ki of
approximately 0.1 nM — among the highest affinities of any statin, 10-fold greater than
simvastatin. By reducing intracellular cholesterol synthesis, statins deplete the hepatocyte
cholesterol pool, triggering SREBP-2 (sterol regulatory element-binding protein 2) activation
and upregulation of LDL receptors. Increased surface LDL receptor expression enhances
clearance of circulating LDL-C and VLDL remnants from plasma. Rosuvastatin at 40 mg/day
achieves approximately 55-65% LDL-C reduction — the greatest of any statin in direct
comparative trials.
Metabolismus
Rosuvastatin undergoes minimal hepatic metabolism, with less
than 10% of the dose metabolized. The primary metabolic pathway is N-demethylation by CYP2C9
to form N-desmethyl rosuvastatin, which retains approximately 50% of HMG-CoA reductase
inhibitory activity. CYP2C9 genetic polymorphisms may modestly influence rosuvastatin exposure.
Unlike lipophilic statins (simvastatin, atorvastatin, lovastatin), rosuvastatin is not
significantly metabolized by CYP3A4, which represents a major clinical advantage: it lacks
interactions with CYP3A4 inhibitors such as macrolide antibiotics, azole antifungals, calcium
channel blockers, and grapefruit juice. This makes rosuvastatin the preferred statin in
patients on multiple CYP3A4-metabolized drugs.
Exkretion
Approximately 90% of rosuvastatin is eliminated unchanged in
feces via biliary excretion; approximately 10% is recovered in urine. The elimination half-life
is approximately 19 hours, enabling once-daily dosing. Because active renal secretion is
minimal, significant accumulation in renal impairment does not occur for the parent drug,
though plasma AUC increases approximately 3-fold in severe renal failure. Asian patients
exhibit approximately 2-fold higher plasma concentrations than Caucasians for a given dose —
attributed to OATP1B1/1B3 transporter polymorphisms — leading to labeling recommendations
for lower starting doses (5 mg) in Asian patients. OATP1B1 *5 allele (c.521T>C, SLCO1B1
rs4149056) is the most important genetic determinant of statin-induced myopathy risk across
all statins, though rosuvastatin's reduced muscle tissue penetration may confer some protection.
Klinische Bedeutung
Rosuvastatin is used for hypercholesterolemia, mixed dyslipidemia,
and primary prevention of cardiovascular events. The JUPITER trial showed 44% reduction in
major cardiovascular events in patients with elevated CRP and normal LDL. The SATURN trial
demonstrated its superior LDL-C lowering vs. atorvastatin. Statin-associated muscle symptoms
(SAMS), ranging from myalgia to rare rhabdomyolysis, are the most clinically significant adverse
effects. Rhabdomyolysis risk is increased by concomitant OATP1B1/3 inhibitors (cyclosporine
increases rosuvastatin AUC 7-fold) or CYP2C9 inhibitors. Small increases in fasting glucose
and new-onset diabetes occur across the statin class. Routine CK monitoring is not recommended
for asymptomatic patients.